Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation

Neurology

Volumn 68, Issue 16, 2007, Pages 1305-1307

  Gorman, M P ^a   Golomb, M R ^b   Walsh, L E ^b,c   Hobson, G M ^d   Garbern, J Y ^e   Kinkel, R P ^f   Darras, B T ^a   Urion, D K ^a   Eksioglu, Y Z ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Division of Pediatric Neurology

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA1A INTERFERON; CORTICOSTEROID; GADOLINIUM; METHYLPREDNISOLONE; OLIGOCLONAL BAND; PROTEOLIPID PROTEIN; STEROID; SYNAPSIN I; TRYPTOPHAN;

ARTICLE; ATAXIA; BRAIN DAMAGE; CASE REPORT; EXON; GENE MUTATION; HORMONE RESPONSE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; NYSTAGMUS; PRIORITY JOURNAL; SCHOOL CHILD; WHITE MATTER;

AMINO ACID SUBSTITUTION; CENTRAL NERVOUS SYSTEM; CEREBELLAR DISEASES; CHILD; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; EXONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE PROTEINS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MUTATION; MYELIN PROTEOLIPID PROTEIN; NEUROPROTECTIVE AGENTS; OLIGOCLONAL BANDS; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 34247259115     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000259522.49388.53     Document Type: Article

References (23)

1. Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur J Hum Genet 2000;8:837-845.
2. Hudson LD. Proteolipid protein gene: Myelin biology and disorders. Lazzarini RA, ed. San Diego: Elsevier Academic Press, 2004.
3. Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics 2005;6:1-16.
4. Saugier-Veber P, Munnich A, Bonneau D, et al. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 1994;6:257-262.
5. Hodes ME, Blank CA, Pratt VM, Morales J, Napier J, Dlouhy SR. Nonsense mutation in exon 3 of the proteolipid protein gene (PLP) in a family with an unusual form of Pelizaeus-Merzbacher disease. Am J Med Genet 1997;69:121-125.
6. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997;3:43-46.
7. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179:973-984.
8. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997;99:1682-1690.
9. A meta-analysis of genomic screens in multiple sclerosis. The Transatlantic Multiple Sclerosis Genetics Cooperative. Mult Scler 2001;7:3-11.
10. Price SE, Sharpe G, Boots A, et al. Role of myelin basic protein and proteolipid protein genes in multiple sclerosis: single strand conformation polymorphism analysis of the human sequences. Neuropathol Appl Neurobiol 1997;23:457-467.
11. Warshawsky I, Rudick RA, Staugaitis SM, Natowicz MR. Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation. Ann Neurol 2005;58:470-473.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. Sivakumar K, Sambuughin N, Selenge B, et al. Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members. Ann Neurol 1999;45:680-683.
14. Lee ES, Moon HK, Park YH, Garbern J, Hobson GM. A case of complicated spastic paraplegia 2 due to a point mutation in the proteolipid protein 1 gene. J Neurol Sci 2004;224:83-87.
15. Battini R, Bianchi MC, Boespflug-Tanguy O, et al. Unusual clinical and magnetic resonance imaging findings in a family with proteolipid protein gene mutation. Arch Neurol 2003;60:268-272.
16. Sporkel O, Uschkureit T, Bussow H, Stoffel W. Oligodendrocytes expressing exclusively the DM20 isoform of the proteolipid protein gene: myelination and development. Glia 2002;37:19-30.
17. Osaka H, Kawanishi C, Inoue K, et al. Novel nonsense proteolipid protein gene mutation as a cause of X-linked spastic paraplegia in twin males. Biochem Biophys Res Commun 1995;215:835-841.
18. Naidu S, Dlouhy SR, Geraghty MT, Hodes ME. A male child with the rumpshaker mutation, X-linked spastic paraplegia/Pelizaeus-Merzbacher disease and lysinuria. J Inherit Metab Dis 1997;20:811-816.
19. Hodes ME, Zimmerman AW, Aydanian A, et al. Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2). Am J Med Genet 1999;82:132-139.
20. Cambi F, Tartaglino L, Lublin F, McCarren D. X-linked pure familial spastic paraparesis: characterization of a large kindred with magnetic resonance imaging studies. Arch Neurol 1995;52:665-669.
21. Shy ME, Hobson G, Jain M, et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003;53:354-365.
22. Wang E, Huang Z, Hobson GM, et al. PLP1 alternative splicing in differentiating oligodendrocytes: characterization of an exonic splicing enhancer. J Cell Biochem 2006;97:999-1016.
23. Ip CW, Kroner A, Bendszus M, et al. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 2006;26:8206-8216.